Cuba develops vaccine against pneumococci
Pneumococci are a group of bacteria that cause diseases such as meningitis, pneumonia and generalized sepsis.
In Cuba there is no product against pneumococci. A project that will have a national vaccine is developed several years ago at the Center for Biomolecular Chemistry (CQB).
The product is right now in the final stages of clinical studies, to obtain registration for the age group of one to five years, but their goal is the under 5 year-old population.
"If, as we hope, the clinical results are successful, we expect in late 2016 or early 2017 we can make a massive immunization campaign in children referred to in that group. A strategy that will allow us to cut the flow of microorganism and impact the disease because it is the population of children under five years, the most prevalent pathologies associated with pneumococcus," stated the degree in biochemistry Darielys Santana Medero, general coordinator of study.